Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 5.2012 million shares [1] - The repurchased shares account for 0.63% of the company's total share capital [1] - The highest transaction price for the repurchased shares was 11.39 yuan per share, while the lowest was 7.52 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, is 50.006 million yuan [1]

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 5.2012 million shares, which represents 0.63% of the company's total share capital [1] - The highest price paid for the repurchased shares was 11.39 yuan per share, while the lowest price was 7.52 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, is 50.006 million yuan [1]

证券代码：603229 证券简称：奥翔药业 公告编号：2025-049 浙江奥翔药业股份有限公司 一、回购股份的基本情况 浙江奥翔药业股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日召开 第四届董事会第六次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司使用自有资金和/或自筹资金以集中竞价交易方式回购公 司已发行的部分人民币普通股（A 股）股票，本次回购的股份拟在未来用于实施股 权激励和/或员工持股计划。本次回购的资金总额不低于人民币 5,000 万元（含）， 不超过人民币 10,000 万元（含），回购价格不超过人民币 14 元/股（含），回购期 限为自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公 司分别于 2025 年 1 月 27 日、2025 年 2 月 6 日披露的《奥翔药业关于以集中竞价 交易方式回购公司股份方案的公告》（公告编号：2025-002）、《奥翔药业关于以集 中竞价交易方式回购股份的回购报告书》（公告编号：2025-005）。 因公司实施 2024 年年度权益分派，自 2025 年 7 月 17 日起，本次回购股份 ...

Core Viewpoint - The company reported a decline in revenue for Q3 2025, with a slight increase in gross margin, while net profit and net profit margin decreased year-on-year and quarter-on-quarter [2] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 646 million yuan, a year-on-year decrease of 6.40%, and a net profit of 207 million yuan, down 9.59% year-on-year [1] - In Q3 2025, the company generated revenue of 164 million yuan, a year-on-year decline of 17.01%, with a net profit of 38 million yuan, down 23.33% year-on-year [2] - The gross margin for Q3 was 53.32%, showing a year-on-year increase of 0.03 percentage points, while the net profit margin was 22.97%, down 1.89 percentage points year-on-year [2] Research and Development - The company has significantly increased its R&D investment, with R&D expenses reaching 81.62 million yuan in the first three quarters of 2025, a year-on-year increase of 27.49%, marking a historical high for the period [3] - The R&D expense ratio for the first three quarters was 12.64%, indicating a commitment to enhancing R&D capabilities and expanding the team to nearly 500 members [3] - The company is focusing on synthetic biology and peptide drugs, with plans to develop innovative drugs, including a new drug for ischemic stroke that is pending entry into phase III clinical trials [3] Future Outlook - The company is expected to see revenue growth in the coming years, with projected revenues of 832 million yuan, 978 million yuan, and 1.213 billion yuan for 2025, 2026, and 2027, respectively [4] - The net profit forecasts for the same years are 241 million yuan, 394 million yuan, and 382 million yuan, with corresponding price-to-earnings ratios of 34, 28, and 22 times [4] - The company anticipates that its collaboration with STADA on a new formulation product will begin contributing to sales in the second half of 2025 [3]

Core Insights - Aoshang Pharmaceutical (603229.SH) reported its Q3 2025 results on October 31, 2025, indicating a total of 53.1 million shares held by six institutional investors, representing 6.40% of the company's total equity [1] Institutional Holdings - The total institutional holding decreased by 1.54 percentage points compared to the previous quarter [1] - The institutional investors include Jiaxing Aoshang Equity Investment Management Partnership, Shanghai Duxi Bingtai Private Fund Management Co., Ltd., Taizhou Jinkong Asset Management Co., Ltd., and others [1] Public Fund and Foreign Investment - There were 68 public funds that did not disclose holdings in this period, including several ETFs focused on the CSI 1000 index [1] - Foreign investment saw a slight increase with one foreign fund, Hong Kong Central Clearing Limited, increasing its holdings [1]

Core Points - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has revised its internal management systems and company charter to enhance governance and compliance with relevant laws and regulations [1][12][16] - The company plans to hold a Q3 2025 performance briefing on November 11, 2025, to discuss its financial results and address investor inquiries [5][6][7] - The company has announced a temporary shareholders' meeting scheduled for November 18, 2025, to discuss various proposals, including the cancellation of the supervisory board and amendments to the company charter [32][33][34] Group 1: Company Governance and Internal Management - The company has revised its charter and internal management systems to improve governance and ensure compliance with the Company Law and Securities Law of the People's Republic of China [1][12] - The revised internal management systems were approved by the board and will take effect after shareholder approval [1][12] Group 2: Q3 Performance Briefing - The Q3 2025 performance briefing will take place on November 11, 2025, from 15:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [5][6] - Investors can submit questions from November 4 to November 10, 2025, and the company will address common concerns during the briefing [5][6][7] Group 3: Shareholders' Meeting - The first temporary shareholders' meeting of 2025 is set for November 18, 2025, with both on-site and online voting options available [32][33][34] - The meeting will discuss the cancellation of the supervisory board and the revision of the company charter, among other matters [32][33][34]

Core Viewpoint - Aoxiang Pharmaceutical is a significant player in the domestic specialty API and pharmaceutical intermediates sector, showcasing strong R&D capabilities and a complete industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Aoxiang Pharmaceutical reported revenue of 646 million yuan, ranking 25th among 47 companies in the industry, with the industry leader, Puluo Pharmaceutical, generating 7.764 billion yuan [2] - The company's net profit for the same period was 207 million yuan, placing it 12th in the industry, while the top performer, Zhejiang Pharmaceutical, achieved 867 million yuan [2] Group 2: Financial Ratios - Aoxiang Pharmaceutical's debt-to-asset ratio stood at 23.30% in Q3 2025, lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin was 56.93%, above the industry average of 35.38%, reflecting robust profitability despite a slight decrease from the previous year's margin of 57.94% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 5.64% to 32,000, while the average number of circulating A-shares held per shareholder decreased by 5.34% to 25,900 [5] - The ninth largest circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 160,600 shares [5] Group 4: Future Outlook - Analysts from Zhongtai Securities noted that while the company faced short-term profit pressure due to product structure changes and increased competition, the growth potential in its formulation and CDMO businesses remains promising [5] - Pacific Securities highlighted that Aoxiang Pharmaceutical's R&D expenses reached a record high in H1 2025, indicating a commitment to innovation, with expectations for revenue growth in the coming years [6]

Core Insights - The company reported a revenue of 646 million yuan for the first three quarters of 2025, representing a year-on-year decline of 6.40% [1] - The net profit attributable to the parent company was 207 million yuan, down 9.59% year-on-year [1] - The non-recurring net profit was 183 million yuan, reflecting a year-on-year decrease of 13.83% [1] - The basic earnings per share stood at 0.25 yuan [1]

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 646 million yuan, representing a year-on-year decrease of 6.4% [1] - The net profit attributable to shareholders of the parent company was 207 million yuan, down 9.59% year-on-year [1] - The basic earnings per share stood at 0.25 yuan [1]

浙江奥翔药业股份有限公司 股东会议事规则 第一章 总则 第一条 为规范浙江奥翔药业股份有限公司（以下简称"公司"）行为，保 证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》《上 海证券交易所股票上市规则》等相关法律法规和《浙江奥翔药业股份有限公司章 程》（以下简称《公司章程》）的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第二章 股东会的一般规定 第四条 公司股东会由全体股东组成。股东会是公司的权力机构，依法行使 下列职权： （一）选举和更换董事，决定有关董事的报酬事项； （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六）对公司合并、分立 ...